Regeneron Pharmaceuticals, Inc… (NASDAQ:REGN)

blue eye

Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration

Ocular Therapeutix Inc. (NASDAQ: OCUL) shares jumped early on Thursday after a new partnership was announced with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Specifically, these companies will collaborate on the development ...
Read Full Story »
Test tubes

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

We have talked in detail about how the political rhetoric has weighed upon the biotech industry. Toss in some scrutiny of pricing over a widely used product, and you have ...
Read Full Story »

8 Top Movers and Hot Stocks for Monday

Stocks overall were fractionally higher early on Monday, August 29, 2016. That makes the big percentages gainers and losers and the companies with big headline news stand out even more than ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: FireEye, Occidental Petroleum, SeaWorld, Teva Pharma, Windstream, Zynga and More

Stocks were indicated to open higher on Friday after an unexpectedly stronger than expected payrolls report. Investors are looking for ways to make money, and they have proven over and ...
Read Full Story »

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

The Nasdaq Biotechnology Index has underperformed the broader market for some time. This year the index is still down about 13%, versus the 6% rise for the S&P 500. We ...
Read Full Story »
Stock Price

Verifone, Biogen Crash Wednesday’s 52-Week Low Club

June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in Wednesday's session. NYSE decliners led advancers by 5 to 4 ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: ArcelorMittal, Boeing, Intel, Schlumberger, Yahoo, Vivint Solar, Johnson & Johnson and More

Stocks were indicated higher yet again on Wednesday, with the Dow over 18,000 and the S&P 500 back at 2,100. The memories of all the selling pressure during the first ...
Read Full Story »
clinical trials

Regeneron Rises on Positive Top-Line Results

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), in conjunction with Sanofi, released top-line results for its most recent late-stage study. The companies announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab ...
Read Full Story »
Pills and tablets

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen Inc. (NASDAQ: AMGN) on a cholesterol drug patent. However, Regeneron ...
Read Full Story »
clinical trials

Regeneron Scores Win in Late-Stage Rheumatoid Arthritis Trial

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
automatic inspection machine

Regeneron Falls on Missed Earnings

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its fourth-quarter financial results before the markets opened on Tuesday. The company had $2.83 in earnings per share (EPS) on $1.10 billion in revenue, ...
Read Full Story »
sadness check box

Regeneron Downgrade Highlights at Least Some Risks

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) seems to have held up rather well against an analyst downgrade on Wednesday. Canaccord Genuity lowered its official rating to Hold from Buy. While the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, AT&T, DuPont, Fitbit, Huntington Bancshares, McDonald’s, Merck, Newmont, Sprint and More

Stocks were indicated lower after companies like Apple, Boeing and AT&T were taking shareholders down after earnings. The volatility in 2016 remains in place. While investors may have seen every ...
Read Full Story »
Biotechnology word cloud

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

If there has been one sector that wishes the 2016 election was already here and gone, it is biotechnology. Shrill political rhetoric over drug pricing and further regulations hammered the ...
Read Full Story »